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AbsTRACT
Objectives To provide an update of the European 
League Against Rheumatism (EULAR) rheumatoid 
arthritis (RA) management recommendations to account 
for the most recent developments in the field.
Methods An international task force considered 
new evidence supporting or contradicting previous 
recommendations and novel therapies and strategic 
insights based on two systematic literature searches on 
efficacy and safety of disease- modifying antirheumatic 
drugs (DMARDs) since the last update (2016) until 2019. 
A predefined voting process was applied, current levels 
of evidence and strengths of recommendation were 
assigned and participants ultimately voted independently 
on their level of agreement with each of the items.
Results The task force agreed on 5 overarching 
principles and 12 recommendations concerning use 
of conventional synthetic (cs) DMARDs (methotrexate 
(MTX), leflunomide, sulfasalazine); glucocorticoids 
(GCs); biological (b) DMARDs (tumour necrosis 
factor inhibitors (adalimumab, certolizumab pegol, 
etanercept, golimumab, infliximab), abatacept, rituximab, 
tocilizumab, sarilumab and biosimilar (bs) DMARDs) and 
targeted synthetic (ts) DMARDs (the Janus kinase (JAK) 
inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). 
Guidance on monotherapy, combination therapy, 
treatment strategies (treat- to- target) and tapering 
on sustained clinical remission is provided. Cost and 
sequencing of b/tsDMARDs are addressed. Initially, MTX 
plus GCs and upon insufficient response to this therapy 
within 3 to 6 months, stratification according to risk 
factors is recommended. With poor prognostic factors 
(presence of autoantibodies, high disease activity, early 
erosions or failure of two csDMARDs), any bDMARD or 
JAK inhibitor should be added to the csDMARD. If this 
fails, any other bDMARD (from another or the same 
class) or tsDMARD is recommended. On sustained 
remission, DMARDs may be tapered, but not be stopped. 
Levels of evidence and levels of agreement were mostly 
high.
Conclusions These updated EULAR recommendations 
provide consensus on the management of RA with 
respect to benefit, safety, preferences and cost.
The European League Against Rheumatism 
(EULAR) developed its first recommendations 
for the management of rheumatoid arthritis (RA) 
with synthetic and biological disease- modifying 
antirheumatic drugs (DMARDs) in 2010.1 They 
summarised the state of the art and provided 
rheumatologists, patients, payers and other stake-
holders with the evidence- based views of Euro-
pean experts on the optimal use and sequence of 
pharmaceutical therapies in patients with RA. Over 
the course of the decade, the development of new 
classification criteria for RA2; novel information 
on optimal clinical targets, such as the American 
College of Rheumatology (ACR)- EULAR remission 
definitions3; evolution of treatment algorithms and 
strategies4 5 and the advent of new drugs6 7 already 
necessitated two updates of the EULAR recommen-
dations.8 9 The ACR, the Asian- Pacific League of 
Associations for Rheumatology (APLAR) and the 
Pan- American League of Associations for Rheu-
matology (PANLAR) have published similar guid-
ance documents, although using slightly different 
approaches.10–12
Today it is widely accepted that clinical remission 
is the main therapeutic target for patients with RA, 
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with low disease activity (LDA) as a best possible alternative, 
and that a treat- to- target (T2T) strategy should be applied when 
treating patients with RA.1 9–11
Although relevant data accrue rapidly, several of the recom-
mendations, even in the 2016 update, were based on rather low 
levels of evidence (LoE) and many have elicited intense debates 
because of variable interpretations of evidence and empirical 
approaches. Three years have passed since the last update.9 
Therefore, it was considered timely to again evaluate informa-
tion regarding:
 ► Newly licensed drugs
 ► Long- term efficacy and safety of long approved agents
 ► Comparative effectiveness studies
 ► Therapeutic targets and treatment strategies
 ► Consideration of safety aspects and costs
 ► Specific items of the 2016 research agenda that have been 
accomplished during the last few years of the decade
The EULAR executive committee approved the proposal to 
update the recommendations. We wished to obtain global input 
and account for views from regions of the world beyond Europe 
and invited rheumatologists from Asia, Latin America and North 
America to contribute to the discussion and phrasing of the 
recommendations.
The major focus of the EULAR recommendations continues 
to be pharmacological therapy with DMARDs. The concept 
of ‘disease modification’ comprises a combination of relief of 
signs and symptoms; improvement or normalisation of physical 
function, quality of life and social and work capacity; and most 
characteristically the inhibition of occurrence or progression of 
structural damage to cartilage and bone. The latter distinguishes 
DMARDs from mere symptomatic agents, such as non- steroidal 
antirheumatic drugs.
The increasing number of effective drugs and modes of action 
(MOAs) has improved the likelihood of reaching the treatment 
target for individuals with RA, but high drug- costs still limit 
widespread use and thus contribute to inequity of access to best 
care across various regions and countries.13–15 The approval and 
advent of biosimilar (bs) DMARDs has introduced price compe-
tition and led to a considerable reduction of the net costs of 
biological (b) DMARDs,16 although this may not be true in all 
countries and may require further exploration. Nevertheless, 
access to optimal care is usually poor in low- income countries, 
but even in some affluent countries payers still do not adhere to 
otherwise widely established standards of care.17 18 Therefore, 
recommendations for the management of patients with RA have 
become increasingly useful in providing physicians, patients, 
health professionals, payers, regulators and others involved in 
healthcare with evidence- based guidance supported by the views 
of experts involved in generating these novel developments. 
Consequently, from their outset, EULAR recommendations 
always addressed cost aspects.1 Indeed, in the recently updated 
EULAR standardised operating procedures (SOPs) on the devel-
opment of recommendations, cost aspects have been included in 
addition to requiring the assessment of evidence on efficacy and 
safety as well as expert opinion.19 This is in line with recommen-
dations by the WHO on rational treatment.20
Herein, we provide the 2019 update of the EULAR RA 
management recommendations.
MeTHOds
After approval by the EULAR executive committee, the 
convener (JSS) and methodologist (RBML) invited a steering 
committee and a task force to work on this update of the EULAR 
recommendations for the management of RA. The 2019 update 
followed the EULAR SOPs for the development of recommenda-
tions19 which also suggest adherence to the Appraisal of Guide-
lines for Research & Evaluation (AGREE) recommendations in 
their updated version (AGREE II).21
steering committee
The steering committee included eight rheumatologists (JWJB, 
GB, MD, RBML, IBM, JSS, RFvV, DvdH), one patient repre-
sentative (MdW) and two fellows (AK, AS) who performed the 
systematic literature research (SLR). This group initially devel-
oped the respective research questions. The SLRs focused on (1) 
efficacy of DMARDs (as monotherapy or combination therapy, 
including conventional synthetic (cs) DMARDs, bDMARDs and 
targeted synthetic (ts) DMARDs), glucocorticoids (GC) and treat-
ment strategies and (2) safety of DMARDs and GC. To this end, 
the SLRs obtained in 201622–24 served as a starting point and a 
systematic analysis of the literature published between 2016 and 
8 March 2019 was performed. New information on treatment 
strategies was also evaluated. In contrast to the previous safety 
SLR which focused on registry data, the current safety SLR also 
addressed data from randomised controlled trials and extension 
studies, since for many new agents registry data are still limited. 
Formal economic analyses were not performed, but cost aspects 
were considered throughout the process in line with the current 
state of the art of developing recommendations.20 25 The two 
rheumatology fellows exploited existing publication databases 
on randomised controlled trials for efficacy and safety, and also 
evaluated recent EULAR and ACR congress abstracts. Summary- 
of- findings tables were generated, a thorough risk- of- bias assess-
ment was performed (for details, see the publications on these 
SLRs)26 27 and LoE and strengths of recommendation (SoR) 
were determined with the standards of the Oxford Centre for 
Evidence Based Medicine.28 The two SLRs informing the task 
force and a detailed description of their methods are published 
separately.26 27 Of note, in the present publication we also use 
references from the 2019 Annual European Congress held in 
June 2019 where it deemed appropriate, or publications that 
appeared after the deadline of the SLRs, 8 March 2019, when 
the contents had previously been covered by abstracts addressed 
in the SLRs, or otherwise newly published information regarding 
efficacy and especially safety that deemed important to be 
included as up- to- date information for the readers at the time 
of submission.
The steering committee discussed the results of the SLRs thor-
oughly and formulated proposals for an update of the recom-
mendations based on this information. The SLR data and the 
suggestions of the steering committee were presented to the 
whole task force for further discussion, development of the 
updated recommendations and voting.
Task force
The task force consisted of 47 individuals, including the steering 
committee members. Among the task force members were three 
patients, two health professionals and two delegates of the 
EULAR young rheumatologists’ network EMEUNET. The rheu-
matologists were all experienced in the treatment of RA and most 
had previously participated in clinical trials; moreover, several of 
them were involved in the analysis of data from their countries’ 
patient registries or in various aspects of outcomes research. The 
patients and health professionals all had a track record of partici-
pating in consensus finding activities, like most of the rheumatol-
ogists. Since we also wished the task force’s work to be informed 
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by rheumatologists from other regions of the world, aside from 
a broad representation from 15 European countries, two rheu-
matologists from Asia, two from Latin America and two from 
North America participated; most had actively engaged in devel-
oping documents of their regional leagues and/or national soci-
eties. All task force members disclosed their potential conflicts 
of interest to the EULAR executive committee before the start 
of the process.
Consensus finding
A few principal considerations were specified upfront. First, 
the previous 2016 version of the recommendations (containing 
4 overarching principles and 12 recommendations) were key 
considerations,9 but were all open to amendment, changes in 
ordering or deletion where appropriate. Second, it was decided 
that existing recommendations should be discussed in the context 
of new evidence. If new evidence contradicting a previous 
recommendation was lacking, the former evidence base had to 
be accepted and the recommendation had to be kept unchanged. 
This approach prevents the intentional or unintentional neglect 
of previous formal task force decisions, which had been based 
on a thorough discussion of existing evidence presented at that 
time, recalibrated and sometimes amended at update proce-
dures; also, they have always been endorsed by voting among 
the previous task force members followed by EULAR’s executive 
committee approval. Third, drugs not (yet) approved in Europe 
but used elsewhere in the world, and unapproved drugs with 
evidence from phase III clinical trials could be considered in the 
recommendations to allow for some anticipation of a potential 
future uptake in clinical practice, appreciating all respective 
caveats. Importantly, drugs can only legally be prescribed after 
their regulatory approval. Also, whereas the recommendations 
address some safety aspects, the readers are referred to the 
summaries of product characteristics (SPCs) for more detailed 
safety information for each of the drugs. Fourth, registry data 
were primarily used for the assessment of rare safety issues but 
not efficacy, since the outcomes of patients included in registries 
are often confounded by indication.
After the presentation of the SLR results and the steering 
committee’s proposals for the amendment of the recommen-
dations, the task force was divided into three breakout groups. 
One group reviewed new evidence related to treatment strat-
egies and targets, focusing also on the overarching principles; 
the second group addressed new evidence regarding bDMARDs 
and tsDMARDs and the third group dealt with new evidence in 
relation to the use of csDMARDs (monotherapy or in combina-
tions) and GC. Respective safety aspects were addressed in each 
of these breakout groups.
After representatives of each breakout group had reported the 
results of the respective discussions and presented proposals for 
the wording of individual recommendations to the whole task 
force for further deliberations, voting took place.
For a change of an existing overarching principle or recom-
mendation to be accepted for the final document, a majority of 
≥75% of the votes was required. Once such change was accepted, 
wording details could undergo further voting. A new recommen-
dation was immediately accepted when ≥75% or more of the 
task force members voted for it. If this result was not achieved, 
the respective text was amended and subjected to a second 
ballot, for which a 67% majority was required. If this ballot was 
not successful, the text was further amended and subjected to 
a third ballot for which a simple (>50%) was required; failing 
that, the proposal was rejected. For new or amended items, the 
results of the respective last ballot are shown as percentage of 
voting members. Notes captured the contents of the discussions 
and the reasoning behind each decision and these are presented 
in the comments accompanying the individual items. At every 
point in time, more than 90% of the members participated in 
the ballots; the percentages shown always relate to per cent of 
present participants in that vote.
After the face- to- face meeting, each recommendation, as 
agreed by the task force, received the appropriate LoE and 
strength of recommendation based on the SLRs. With this 
information added, the recommendations were subjected to 
an anonymous electronic assessment (by email) on the levels of 
agreement (LoA). Each recommendation received an assessment 
on a scale of 0–10 with 0 meaning no agreement whatsoever and 
10 full agreement; the mean values of these votes are presented.
The draft of the manuscript was sent to all task force members 
for their comments. After incorporation of these comments, the 
manuscript was submitted to the EULAR executive committee 
for review and approval. The comments obtained from the exec-
utive committee were also addressed, and the final version of the 
manuscript was then submitted to the journal for peer review.
ResulTs
The 2019 update of the EULAR RA management recommenda-
tions reflects the balance of clinical, functional and structural 
efficacy; safety; costs; and patients’ perceptions as evaluated by 
the task force. Drug toxicity was discussed and considered, but 
the respective data are presented primarily in the safety SLR,26 
because it is assumed that prescribers should be aware of the 
safety information provided in the SPCs of the various agents. 
EULAR has developed a series of documents addressing safety 
of drugs used for the treatment of RA,29–35 and various other 
publications have focused on these aspects.36–42 In particular, 
as suggested by the safety SLR, the major risk of bDMARDs 
and tsDMARDs is related to infections. Recommendations 
for vaccination33 as well as a score allowing calculation of the 
risk of infection in patients exposed to bDMARDs have been 
developed.41 43 44 Nevertheless, when toxicity constitutes a 
major or unexpected problem, a specific warning is provided 
in this document. Of note, the two SLRs26 27 as well as the 
text accompanying each item should be regarded as part and 
parcel of these recommendations, since the individual bullet 
points represent only abbreviated versions of the discussions 
and conclusions.
When classifying DMARDs, the task force adhered to the 
previously used nomenclature8 45 as shown in table 1. This 
table also provides a glossary of terms employed in the present 
document. The task force did not distinguish between early and 
established RA but rather between three phases of the treatment 
process by differentiating between patients who are naive to 
any DMARD therapy (phase I), patients who had an insufficient 
response (IR) to initial course(s) of csDMARDs (phase II) and 
those who had an IR to a first bDMARD or tsDMARD (phase 
III). There is currently no evidence for differential responses 
solely based on disease duration, apart from differences in base-
line damage due to delayed treatment initiation and consequent 
risk of damage progression. The task force also took prognostic 
factors (table 1) into account, which have similar predictive 
power irrespective of disease duration.46 47 Of note, recommen-
dations for the management of early arthritis, including undif-
ferentiated arthritis, have been updated recently.48 The present 
recommendations do not address the management of patients 
with undifferentiated arthritis or arthralgia in patients who may 
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Table 1 Glossary and definitions (after9)
Term definition
Poor prognostic factors  ► Persistently moderate or high disease activity 
despite conventional synthetic DMARD (csDMARD) 
therapy according to composite measures including 
joint counts
 ► High acute phase reactant levels
 ► High swollen joint count
 ► Presence of RF and/or ACPA, especially at high 
levels
 ► Presence of early erosions
 ► Failure of two or more csDMARDs
Low- dose glucocorticoids <7.5 mg/day (prednisone equivalent)
Tapering  ► Reduction of drug dose or increase of application 
interval
 ► May include cessation (tapering to 0), but then only 
after slow reduction
Cessation, stopping  ► Stopping of a particular drug
disease activity states
Remission ACR- EULAR remission definition (Boolean or index 
based)
Low disease activity Low disease activity state according to any of the 
validated composite disease activity measures that 
include joint counts
Moderate, high disease 
activity
Respective disease activity state according to any of 
the validated composite disease activity measures that 
include joint counts
dMARd nomenclature
Synthetic DMARDs
csDMARDs Eg, methotrexate, 
leflunomide, sulfasalazine, 
hydroxychloroquine
Targeted synthetic 
DMARDs
Eg, baricitinib, tofacitinib, 
upadacitinib
Biological DMARDs
Biological originator 
DMARDs
TNFi: adalimumab, 
certolizumab, etanercept, 
golimumab, infliximab; IL- 
6Ri: sarilumab, tocilizumab;
Costimulation- i: abatacept; 
anti- B cell (CD20): 
rituximab
Biosimilar DMARDs (currently for: adalimumab, 
etanercept, infliximab, 
rituximab)
ACPA, anticitrullinated protein antibody; ACR, American College of Rheumatology; 
cs, conventional synthetic; DMARDs, disease- modifying antirheumatic drugs; EULAR, 
European League Against Rheumatism; IL- 6Ri, interleukin 6 receptor inhibitor; RF, 
rheumatoid factor; TNFi, tumour necrosis factor inhibitor.
be at risk of developing RA, but only patients with RA from the 
time of diagnosis.
Overarching principles
As before, the task force reinforced the necessity to adhere to 
some general principles when treating patients with RA, the 
so- called overarching principles (table 2). These principles 
constitute the foundation on which the actual recommendations 
are based. By their common sense nature, they cannot be based 
on specific scientific evidence. Until 2013, there were three over-
arching principles; in 2016, the task force added a fourth one as 
overarching principle B. Now yet another item appeared neces-
sary as overarching principle D, resulting in five overarching 
principles for the 2019 update (table 2).
A. Treatment of patients with RA should aim at the best care and 
must be based on a shared decision between the patient and 
the rheumatologist. This principle remained unchanged in 
wording and placement. During discussion, the importance 
of shared decision- making was reiterated and the importance 
of patient education emphasised. Indeed, patient education 
may increase adherence to medication49; moreover, educa-
tion of rheumatologists may foster adherence to appropri-
ate assessment strategies.50 There were suggestions made to 
expand this item by mentioning the importance of patient 
education separately, but there was ultimate agreement that 
patient education forms the implicit and inseparable basis for 
shared decision- making. Nevertheless, since shared decision- 
making is so important, communication skills should also be 
a focus of rheumatologists and other health professionals. 
This item is also included in a publication on quality indi-
cators that should be incorporated in the decision process.51 
It should also be noted that the focus of the task force was 
on DMARDs and not on other pharmacological and non- 
pharmacological therapies which may have to be considered 
in many patients as adjunctive therapies for best care. The 
task force agreed at a level of 9.7 (SD 1.1) with this principle.
B. Treatment decisions are based on disease activity, safety is-
sues and other patient factors, such as comorbidities and 
progression of structural damage. Added in 2016 and re-
maining unchanged, this principle is particularly important 
when considering the use of bDMARDs and tsDMARDs. 
The higher risk of herpes zoster infections on JAK- inhibitors, 
more pronounced in some Asian countries such as Japan and 
South Korea, is captured under this principle. The prevalent 
discussion on the risk of venous thromboembolic events 
(VTEs), such as in relation to obesity or a history of prior 
VTE events, has also been addressed.52 53 To this end, there 
was a debate about whether the term ‘risk’ should be more 
explicitly added to this overarching principle, but it was then 
agreed that the terms ‘comorbidities and safety issues’ inher-
ently include risk assessment, and obesity, for example, also 
constitutes a comorbidity. It was decided to mention these 
deliberations in the explanatory text and leave the principle 
unchanged. LoA 9.8 (0.5).
C. Rheumatologists are the specialists who should primarily care 
for patients with RA. Unchanged from previous recommen-
dations, this principle addresses the importance of specialty 
care for a complex disease like RA,54–58 since rheumatolo-
gists possess the optimal depth and breadth of experience 
regarding the use of all types of DMARDs, including efficacy 
outcomes, risk assessment and knowledge of comorbidities 
(as discussed under item B). Importantly, health professionals 
such as rheumatology nurse specialists also take care of many 
aspects related to the management of RA and patient educa-
tion. The rheumatologist often leads a multidisciplinary team 
in the course of providing ‘best care’ in accordance with item 
A. On the other hand, in certain areas of the world rheuma-
tology training is not sufficiently available and other experts 
may care for patients with RA, hence the term ‘primarily’. 
Moreover, some comorbidities, such as chronic hepatitis, in-
terstitial lung disease or cardiovascular events, may require 
consultation with, and treatment by, other specialists. To-
gether with item D, this principle achieved the highest LoA 
9.9 (0.4).
D. Patients require access to multiple drugs with different MOAs 
to address the heterogeneity of RA; they may require multi-
ple successive therapies throughout life. Developing this new 
overarching principle was considered necessary and timely, 
in view of the increasing number of drugs available to treat 
RA. We now recognise five molecular target families (tumour 
necrosis factor (TNF), interleukin 6 (IL-6), CD80/86, CD20 
and Janus kinases (JAK)) with multiple drugs for several of 
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Table 2 The 2019 updated EULAR RA management recommendations
Overarching principles loe soR loA
A Treatment of patients with RA should aim at the best care and must be based on a shared decision between 
the patient and the rheumatologist.
n.a. n.a. 9.7
B Treatment decisions are based on disease activity, safety issues and other patient factors, such as comorbidities 
and progression of structural damage.
n.a. n.a. 9.8
C Rheumatologists are the specialists who should primarily care for patients with RA. n.a. n.a. 9.9
D Patients require access to multiple drugs with different modes of action to address the heterogeneity of RA; 
they may require multiple successive therapies throughout life.
n.a. n.a. 9.9
E RA incurs high individual, medical and societal costs, all of which should be considered in its management by 
the treating rheumatologist.
n.a. n.a. 9.4
  Recommendations       
1. Therapy with DMARDs should be started as soon as the diagnosis of RA is made. 1a A 9.8
2. Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.* 1a A 9.7
3. Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 
3 months after the start of treatment or the target has not been reached by 6 months, therapy should be 
adjusted.
2b B 9.3
4. MTX should be part of the first treatment strategy. 1a A 9.4
5. In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be 
considered as part of the (first) treatment strategy.
1a A 9.0
6. Short- term glucocorticoids should be considered when initiating or changing csDMARDs, in different dose 
regimens and routes of administration, but should be tapered as rapidly as clinically feasible.
1a A 8.9
7. If the treatment target is not achieved with the first csDMARD strategy, in the absence of poor prognostic 
factors*, other csDMARDs should be considered.
5 D 8.4
8. If the treatment target is not achieved with the first csDMARD strategy, when and poor prognostic factors* are 
present, a bDMARD† or a tsDMARD‡ should be added.
1a A 9.3
9. bDMARDs and tsDMARDs should be combined with a csDMARD; in patients who cannot use csDMARDs 
as comedication, IL-6 pathway inhibitors and tsDMARDs may have some advantages compared with other 
bDMARDs.
1a A 8.9
10. If a bDMARD# or tsDMARD## has failed, treatment with another bDMARD† or a tsDMARD‡ should be 
considered; if one TNF inhibitor therapy has failed, patients may receive an agent with another mode of action 
or a second TNF inhibitor.
#1b
##5
A
D
8.9
11. If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering bDMARDs 
or tsDMARDs, especially if this treatment is combined with a csDMARD.
1b A 9.2
12. If a patient is in persistent remission, tapering the csDMARD could be considered. 2b B 9.0
*For definitions of remission, low disease activity and poor prognostic factors, see table 1.
†Abatacept, rituximab, sarilumab, tocilizumab and TNF inhibitors: adalimumab, certolizumab pegol, etanercept, golimumab,infliximab (whether boDMARDs or EMA- approved/
FDA- approved bsDMARDs).
‡Janus kinase inhibitors.
bDMARDs, biological DMARDs; boDMARDs, biological originator DMARDs; bsDMARD, biosimilar DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, disease- 
modifying antirheumatic drugs; EMA, European Medicines Agency; EULAR, European League Against Rheumatism; FDA, Food and Drug Administration; IL-6, interleukin 6; JAK, 
Janus kinase; LoA, levels of agreement; LoE, levels of evidence (according to the standards of the Oxford Centre for Evidence Based Medicine); MTX, methotrexate; n.a., not 
applicable; RA, rheumatoid arthritis; SoR, strengths of recommendation; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs (currently Janus kinase inhibitors).
these molecules. Treating toward a target of remission or 
LDA (see recommendations 2 and 3) potentially requires 
switching between drugs (cycling), sometimes even as early 
as every 3 months if improvement in accordance with stra-
tegic principles (see recommendations 2 and 3) is not suffi-
cient. Moreover, it is well established that after failure of one 
drug, a different drug belonging to the same class, that is, tar-
geting the same molecule, can still be efficacious. Therefore, 
patients, rheumatologists and payers must be aware that mul-
tiple successive drug options are often needed to reach the 
therapeutic goal. This does not necessarily incur extra cost, 
since continuing a (partially) failing DMARD can be as cost-
ly as switching to another DMARD. This item addresses an 
additional important characteristic: RA is a lifelong disease 
whose cause is unknown and which—like many other chron-
ic disorders—cannot currently be cured in most patients, but 
can be brought into remission or at least LDA in the vast 
majority of patients with appropriate treatment adaptations 
using the whole spectrum of therapies available to us today. 
Thus, remission on drug is the best we can usually achieve, 
with subsequent dose reduction representing a viable option. 
While the approach to taper medication is addressed in rec-
ommendations 11 and 12, patients, rheumatologists, payers 
and society must realise that many patients will not be able to 
stop therapy and may require lifelong treatment. Up to 50% 
of patients starting a new DMARD must stop it within 12 to 
18 months for insufficient efficacy or adverse events.59 60 In-
deed, many patients still do not reach the therapeutic targets, 
despite all of our modern therapies and therapeutic strate-
gies, but still about 10%–20% of patients who fail multiple 
drugs have a good treatment response to yet another agent.61 
The major weakness of our current treatment approaches 
is the lack of biomarkers for immediate stratification of an 
individual patient to the most appropriate drug. Important-
ly, these considerations emphasise the need to search for 
predictive markers; however, since a considerable number 
of patients (about 20%–30%) are refractory to all current 
treatment options, new therapies also need to be developed. 
Among the task force members, 100% agreed to add this 
principle and to its wording and placement. LoA 9.9 (0.4).
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E. RA incurs high individual, medical and societal costs, all of 
which should be considered in its management by the treating 
rheumatologist. This (unchanged) principle reminds all stake-
holders of an important balance. On the one hand, effective 
RA therapy can reduce the economic burden on individual 
patients, their families and society. This economic burden 
not only includes direct medical costs but also indirect costs 
due to sick leave, work disability and premature retirement. 
On the other hand, the high price of many current drugs 
causes a net increase in the economic burden to society. So 
when making therapeutic decisions, drugs that are less costly 
must be preferred over more costly ones, as long as they are 
similarly efficacious and safe and in line with the therapeu-
tic paradigms.20 As mentioned in the introduction, in many 
countries, the high costs of treatment limit the availability of 
modern therapies (inequity),14 the availability of biosimilars 
can address this and provide significant reductions of health-
care budgets, when their price is sufficiently low and their 
application is then reinforced by payers or politicians.16 62 
The task force voted unanimously to place this item as the 
last overarching principle, without a change in wording. LoA 
9.4 (1.4).
Individual recommendations
General aspects
The task force’s discussions resulted in 12 recommendations. 
The first seven recommendations as well as recommendations 
9 and 12 remain unchanged. The background and evidence for 
these items have been presented previously, and in this respect 
the reader is referred to the 2016 update.9 Each was briefly or 
more extensively discussed. This was not the case for the afore-
mentioned nine unchanged items. Note that the evidence base 
was carried forward from last time (or when new data were avail-
able adapted accordingly) and that all items whether changed or 
unchanged underwent a new assessment for the LoA.
As before, the recommendations are ordered in a way that 
allows their sequential use, and the respective algorithm is 
depicted in figure 1. The recommendations start with the 
approach to patients with newly diagnosed RA, then address 
both specific drugs and treatment strategies for these patients as 
well as those who already failed specific therapies, and end with 
proposals for tapering therapy under appropriate preconditions.
Recommendations
1. Therapy with DMARDs should be started as soon as the diag-
nosis of RA is made. This unchanged item represents the basic 
principle of RA treatment that initiation of DMARD therapy 
should be immediate, since the disease will not remit sponta-
neously. LoE 1a, SoR A, LoA 9.8 (0.6).
2. Treatment should be aimed at reaching a target of sustained 
remission or LDA in every patient (unchanged). This is a central 
theme in the care of patients with RA, and in line with the T2T 
recommendations by an international task force.5 The instru-
ments that should be used to define remission or LDA were not 
any more discussed (table 1) and the reader is referred to the 
T2T recommendations and previous deliberations.3 5 9 Indeed, 
ACR and EULAR have agreed on the Boolean- based and index- 
based remission definitions (the latter using the simplified or 
clinical disease activity index SDAI, CDAI).3 As set forth as prin-
ciple A, the treatment target has to be agreed in a process of 
shared decision- making. LoE 1a, SoR A, LoA 9.7 (0.6).
3. Monitoring should be frequent in active disease (every 1–3 
months); if there is no improvement by at most 3 months after 
the start of treatment or the target has not been reached by 6 
months, therapy should be adjusted (unchanged). One should 
consider the desired treatment target as well as various patient 
factors, including comorbidities, when making treatment adap-
tations. A rapid attainment of the selected target endpoint is now 
regarded as being of critical importance: while direct evidence 
for the question of the best time point for decision- making 
regarding change of therapy is still lacking, it is known that if 
disease activity fails to improve by at least 50% within 3 months, 
the probability of reaching the treatment goal of remission (or 
LDA) is low.63 64 Also, the decision to use specific instruments 
should take into account the direct effects of IL-6 and JAK inhib-
itors (JAKis) on the production of acute phase reactants (poten-
tially independent of clinical improvements, but more reflecting 
pharmacodynamic effects).65 66 This recommendation remained 
unchanged. LoE 2b, SoR B, LoA 9.3 (0.8).
4. Methotrexate (MTX) should be part of the first treatment 
strategy (unchanged). MTX remains the anchor drug in RA; not 
only is it an efficacious csDMARD by itself but it is also the 
basis for combination therapies, either with GC or with other 
csDMARDs, bDMARDs or tsDMARDs. It is important to reit-
erate that MTX (whether administered orally or subcutane-
ously) should be escalated to a weekly dose of about 0.3 mg/
kg67 and that this escalation should be done within 4–6 weeks. 
In the Western hemisphere, the optimal therapeutic dose will be 
around 20–25 mg68 per week, while in Asia—in line with a lower 
body weight and possibly different pharmacogenetics in the East 
Asian population—the maximum dose will be lower, such as 16 
mg in Japan.69 The importance of folic acid supplementation 
is another central aspect of MTX therapy. Patients often asso-
ciate MTX with a variety of adverse events that are primarily 
related to its use as medication for malignancies at high doses; 
therefore, in the course of the shared decision- making process 
patient education and information, including addressing fears of 
potential side effects, is as important for this ‘old’ drug as it is 
for novel agents.
As in the past, there were some discussions whether the first 
treatment strategy should already potentially include a bDMARD 
or tsDMARD, but this was not further pursued since no new 
evidence has been seen suggesting that the current approach—
especially considering recommendation 6—should be changed. 
Indeed, no bDMARD plus MTX has yet shown superiority 
compared with MTX plus GC in MTX- naive patients,70 71 and 
tsDMARDs have not yet been compared with MTX plus GC as 
starting therapy. Moreover, there is no longer- term disadvantage 
taking this approach, since initiation of MTX in patients with 
early RA and subsequent addition of a TNF inhibitor (TNFi) at 
6 months in case of an IR confers similar overall results as using 
the combination of MTX and a TNFi from the start, with many 
patients having already achieved the therapeutic target without 
the use of a bDMARD.72 Thus, this decision was based on both 
the evidence base regarding efficacy and safety of different 
initial therapeutic approaches in patients with early RA and on 
economic considerations. LoE 1a, SoR A, LoA 9.4 (1.2).
5. In patients with a contraindication to MTX (or early intol-
erance), leflunomide or sulfasalazine should be considered as part 
of the (first) treatment strategy (unchanged). There was a brief 
discussion whether a direct step to a bDMARD or tsDMARD 
should be considered if MTX was contraindicated, but no 
evidence comparing any of these agents in monotherapy with 
leflunomide or sulfasalazine in combination with GC is currently 
available. It was also suggested that antimalarials should be 
added to this recommendation. Indeed, as discussed in previous 
documents, antimalarials and especially hydroxychloroquine, 
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Figure 1 Presentation of the 2019 update of the EULAR RA management recommendations in form of an algorithm. This is an abbreviated 
version aiming to provide a general overview, but it must be borne in mind that the algorithm cannot be separated from the details presented in 
the discussion of the individual recommendations in the paper which are part and parcel of these recommendations. ACPA, anticitrullinated protein 
antibody; ACR, American College of Rheumatology; bDMARDs, biological DMARDs; bsDMARD, biosimilar DMARDs; csDMARDs, conventional synthetic 
DMARDs; DMARDs, disease- modifying antirheumatic drugs; EMA, European Medicines Agency; EULAR, European League Against Rheumatism; FDA, 
Food and Drug Administration; IL- 6R, interleukin 6 receptor; JAK, Janus kinase; MTX, methotrexate; RA, rheumatoid arthritis; RF,rheumatoid factor; 
TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.
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have a limited place, mainly reserved for patients with mild RA. 
As no new evidence regarding a good efficacy of hydroxychlo-
roquine was found for RA in general and the historic studies 
had shown only weak clinical and no structural efficacy,73 it was 
decided to keep the focus on sulfasalazine and leflunomide. In 
some countries, especially in Asia, also other agents like bucilla-
mine or iguratimod have been approved for RA, but these drugs 
were not considered here given insufficient data in other regions. 
LoE 1a, SoR A, LoA 9.0 (1.2).
6. Short- term GC should be considered when initiating or 
changing csDMARDs, in different dose regimens and routes of 
administration, but should be tapered as rapidly as clinically 
feasible (unchanged). There was much less discussion on the 
use of GC than ever before in the history of these recommen-
dations, and there was unanimity that they should primarily be 
used as bridging therapy until csDMARDs exhibit their efficacy 
and that tapering GC rapidly (aiming at discontinuation within 
about 3 months) is important. Failure to sustain the treatment 
target on tapering or withdrawal of GC after the bridging phase 
should be regarded as failure of this therapeutic phase and thus 
elicit the institution of a bDMARD or a tsDMARD added to the 
csDMARD. Regarding the debate over whether treatment with 
bDMARDs or tsDMARDs should be preferred to csDMARDs 
plus GC, at least three trials have shown similar responses when 
MTX plus GC was compared with MTX plus bDMARDs70 71 74 
and no new data conflicting with this view have been published 
since then; tsDMARDs have not yet been compared with MTX 
plus GC. LoE 1a, SoR A, LoA 8.9 (1.3).70 71 74
7. If the treatment target is not achieved with the first 
csDMARD strategy, in the absence of poor prognostic factors, 
other csDMARDs should be considered (unchanged). Poor prog-
nostic factors were defined many years ago and are shown in 
table 1. They include high disease activity, presence of erosions 
and autoantibody positivity at high titres, but also failure to 
achieve LDA after the application of at least two csDMARDs. 
It was suggested that failure of an initial treatment with MTX 
plus GC was also included in this list; however, this proposal did 
not find sufficient backing by the task force. Since the addition 
of GC both to a first csDMARD and to a subsequent csDMARD 
therapy is highly recommended (see item 6: ‘or changing 
csDMARDs’), consideration of ‘other csDMARDs’ here means 
either switching to or addition of another csDMARD. As detailed 
in 2016, combinations of csDMARDs are not regarded as supe-
rior to MTX monotherapy by the task force, especially if MTX 
is combined with GC.75 One study (CareRA) evaluated patients 
with early RA with high and low risk and showed that a milder 
intervention (MTX compared with MTX+GC) also resulted in 
similar outcomes,75 but there are no studies available that have 
evaluated such a strategy in patients who have failed MTX. On 
the other hand, it is known that patients who fail MTX often 
do respond to a subsequent csDMARD course.76 LoE 5, SoR D, 
LoA 8.4 (1.6).
8. If the treatment target is not achieved with the first csDMARD 
strategy and poor prognostic factors are present, a bDMARD or a 
tsDMARD should be added. In 2016, this recommendation read 
as follows: “If the treatment target is not achieved with the first 
csDMARD strategy, when poor prognostic factors are present, 
addition of a bDMARD or a tsDMARD should be considered; 
current practice would be to start a bDMARD.” Thus, there 
are two major changes in the 2019 update. First, the task force 
revised the preference of bDMARDs over tsDMARDs because 
of new evidence regarding the successful long- term efficacy and 
safety of JAKis.77–79 Second, it recommended that a bDMARD 
should be ‘added’ rather than ‘considered’.
Regarding the first change, the task force also agreed that 
bDMARDs and tsDMARDs have on average similar efficacy 
and, therefore, no preference can be given to any of these agents 
for reasons of efficacy. While two studies designed as non- 
inferiority trials have shown statistical superiority of baricitinib 
or upadacitinib compared with adalimumab (all in combination 
with MTX),80 81 a third study using tofacitinib+MTX did not 
show such superiority82; thus, the overall clinical relevance of 
small differences in clinical trials was not considered convincing 
enough for the task force to prefer tsDMARDs over bDMARDs. 
This conclusion is further supported by recently presented data 
revealing that filgotinib+MTX met non- inferiority for Disease 
Activity Score 28 <3.2, but not superiority criteria, when 
compared with adalimumab, a prespecified endpoint, although 
superiority was observed for some of the secondary endpoints.83 
Importantly, in these studies various inflammatory markers, such 
as swollen joint counts, did not differ among the groups, in line 
with the hitherto unknown clinical relevance mentioned above.
A third JAKi, peficitinib, has meanwhile been approved in 
Japan where clinical trials revealed significant efficacy84 85; in a 
global study, efficacy was not similarly apparent, possibly due to 
high placebo effects.86
A fourth JAKi, upadacitinib, has undergone testing in phase 
III trials in different RA populations as combination and mono-
therapy,27 adding to the documented efficacy of this class of 
drugs; upadacitinib has meanwhile been approved at 15 mg daily 
by the FDA of the USA with a variety of warnings added to the 
prescribing information, including a warning that thromboses 
have occurred in patients treated with JAKis87; also EMA has 
given a positive opinion on upadacitinib.
For a fifth JAKi, filgotinib, publication of further phase III trial 
results is awaited and the drug is currently undergoing regula-
tory evaluation.
With respect to safety, beyond what was known to the last 
task force and further corroborated in the course of the current 
safety SLR such as an increased risk of herpes zoster infections,26 
a new safety issue, namely VTEs including pulmonary embolism, 
has emerged for both baricitinib (4 mg daily)88 and tofacitinib 
(at both 5 mg and especially 10 mg twice daily particularly in 
patients with risks of thromboembolic events and higher age).89 
These latter data on tofacitinib are derived from an interim anal-
ysis of study A3921133 (NCT02092467), an ongoing study that 
compares tofacitinib at 5 and 10 mg twice daily with TNF inhi-
bition regarding major cardiovascular events and malignancy in 
patients with RA and at least one cardiovascular risk factor.90 
Thromboembolic events have also been observed with upadac-
itinib.91 92 VTEs are seen especially in patients with a high risk 
for these events (see safety SLR), such as those with a previous 
history of thromboembolic events, those with high body mass 
index, those with hormone replacement therapy and higher 
age.88 93 Therefore, JAKi should be used with caution in patients 
with high risk of TE events. Moreover, currently information 
regarding this risk is not yet final and further accruing, and it 
is not understood which mechanisms may drive this risk; this 
should become a major target of research.
Thus, the decision which drug to prescribe when a patient 
has failed to reach the treatment target with the first therapeutic 
strategy and has unfavourable prognostic markers should be 
based on an aggregate of contraindications, patient preference 
and costs.
The second change that a bDMARD or tsDMARD should be 
‘added’ rather than ‘considered’ constitutes a stronger support 
for combination therapy (item 9) than before. In previous years, 
the SLRs have revealed evidence of similar efficacy among the 
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bDMARDs,23 and this obviously includes biosimilars approved 
by European Medicines Agency (EMA) or US Food and Drug 
Administration (FDA).27
No new studies on the efficacy of csDMARDs after prior 
failure of MTX (or other csDMARDs) have been performed 
since the last update, but during the discussions of the last update 
sufficient evidence was found showing that the benefit of this 
approach is limited and progression of damage may accrue.94 95 
Given that the costs of bDMARD and tsDMARD have decreased 
in many countries since the advent of biosimilars, the task force 
members felt that this recommendation should be reinforced. 
Some participants suggested applying a similar recommendation 
even for patients who do not exhibit poor prognostic factors 
(item 7), but this suggestion did not find sufficient resonance 
in the task force. On the other hand, no study has directly 
compared the benefit of add- on bDMARDs or tsDMARDs vs 
a second course of csDMARDs (plus GCs) in patients without 
poor prognostic factors who failed a first course of MTX; 
this has not even been done for patients with poor prognostic 
factors. This continues to be part of the research agenda. The 
new wording was approved by 95% of the participants. LoE for 
general efficacy: 1a (regarding its primary use in patients with 
poor prognostic factors: 5), SoR A (D), LoA 9.3 (1.0).
9. bDMARDs and tsDMARDs should be combined with a 
csDMARD; in patients who cannot use csDMARDs as comedi-
cation, IL-6 pathway inhibitors and tsDMARDs may have some 
advantages compared with other bDMARDs (unchanged). The 
task force reiterated that—in contrast to clinical practice where 
up to 40% of patients are on bDMARD monotherapy—combi-
nation therapy is advantageous with respect to efficacy compared 
with monotherapy for all bDMARDs and tsDMARDs and with 
respect to immunogenicity for all bDMARDs. When MTX is part 
of such combination therapy, high MTX doses may not be neces-
sary: in combination with TNFi (and presumably other thera-
pies), 10 mg/week may be sufficient96 97 to increase the efficacy 
of the bDMARD. Tocilizumab and sarilumab as monotherapy 
are more efficacious than adalimumab monotherapy and JAKi 
monotherapy generally also has good clinical efficacy. In light of 
these observations, the task force discussed if the second part of 
the sentence should read ‘should be preferred’ rather than ‘may 
have some advantages’, but this proposal did not reach a 75% 
majority. LoE 1a, SoR A; LoA 8.9 (1.1).
10. If a bDMARD or tsDMARD has failed, treatment with 
another bDMARD or a tsDMARD should be considered; if one 
TNFi therapy has failed, patients may receive an agent with 
another MOA or a second TNFi. The first part of this recom-
mendation remains unchanged. The second part underwent a 
slight modification by changing the sequence: the task force now 
placed ‘another MOA’ before ‘a second TNFi’. This amendment 
was based on some reports from registry data, observational 
studies and a randomised controlled trial suggesting that using 
another MOA leads to better efficacy than a second TNFi.98–100 
However, these and similar other studies may have had a high 
risk of bias and, as detailed in the previous SLR, a meta- analysis 
of randomised controlled trials performed in patients with 
an IR to TNFis did not reveal differences in efficacy between 
switching to a second TNFi and using a different drug class,23 
although these were separate and not head- to- head studies. This 
recommendation does not only relate to failure of TNFi, but 
rather to failure of any bDMARD or tsDMARD. While data for 
the efficacy of TNFi after failure of another TNFi have been 
available for long.101–103 At the time of the SLRs, no data were 
available regarding studies of (1) IL- 6R inhibitors after prior 
failure of another such compound (eg, sarilumab after failure 
of tocilizumab), (2) JAKis after failure of another one (eg, baric-
itinib after IR to tofacitinib or (3) bDMARDs after failure of 
tsDMARDs. However, since then a recent post- hoc analysis of 
a clinical trial suggested also some efficacy of sarilumab after 
failure of tocilizumab104 and a study using a TNFi after IR to 
a JAKi was published, revealing similar overall outcomes as 
switching from a TNFi to a JAKi.105 Needless to say that the 
term ‘second TNFi’ does not relate to a biosimilar of the failed 
compound but to a molecularly different TNFi. Among the task 
force members, 84% agreed with the change. The LoE continues 
to be 1a for patients who did not sufficiently respond to TNFis 
(SoR A); JAK inhibition was studied in RCTs after failure of 
several bDMARDs.91 106 LoE 1a, SoR A; LoA 8.9 (1.2).
11. If a patient is in persistent remission after having 
tapered glucocorticoids, one can consider tapering bDMARDs 
or tsDMARDs, especially if this treatment is combined with a 
csDMARD. In this update, the term ‘tsDMARD’ was now 
included, based on respective trial data.107 Otherwise the recom-
mendation remained unchanged. In the discussions, the task 
force members reinforced the proposed sequence (stopping GCs 
first and subsequently, when the treatment target is sustained, 
reducing bDMARDs or tsDMARDs). With the reiteration of this 
principle (‘persistent remission’ recommended before starting 
drug tapering) which has been introduced already in 2010 
and maintained ever since, because no conflicting data became 
available, the task force explicitly affirmed the requirement 
of persistent remission before initiation of dose reduction or 
interval increase of bDMARDs or tsDMARDs. It is important to 
mention that discontinuation of bDMARDs is frequently associ-
ated with flares (increasing with time since discontinuation) and 
that, therefore, many task force members would have preferred 
to see tapering just as a dose reduction or interval increase rather 
than leading to discontinuation; however, the vast majority 
(>80%) of patients who flare can regain a good outcome on 
reinstitution of the previous treatment.107 108
A definition for the term ‘persistent’ is not available, since no 
study investigated whether 3, 6 or 12 months of stringent remis-
sion is more appropriate for such definition; in some studies, 6 
months of remission was used for this purpose, but this needs to 
be part of the research agenda. Several studies showed a clear 
correlation of flare risk with failure to achieve ‘deep’ or ‘strin-
gent’ remission prior to bDMARD tapering107 109–112; however, 
this was not definitely established in a recent systematic liter-
ature review because of conflicting study data,113 Flares after 
bDMARD tapering are associated with a progression of joint 
damage, especially when leading to long- term increase in disease 
activity,114 115 while progression of damage may not be seen with 
short lived flares.115 Importantly, also small increases in joint 
damage may become significant over years and lead to irrevers-
ible disability.115
Thus, overall, persistent ACR- EULAR remission is associated 
with lowest risk of flares and tapering while in LDA (including 
other, less stringent states previously termed remission) is not 
recommended because of a higher risk of flares.114 Further, 
tapering may have to be approached particularly carefully in 
patients who have joint damage, since these patients have a 
high risk of damage progression on complete withdrawal of 
bDMARDs, similar to patients with elevated levels of acute 
phase reactants or residual (low) disease activity, which is not 
seen on dose reduction.114 As an additional discussion point 
in this respect, it was suggested to consider continuing the 
bDMARD (or tsDMARDs) while stopping the accompanying 
csDMARD. However, a recent randomised trial investigating this 
question yielded no difference in outcomes between these two 
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box 1 Continued
24. How long should the duration of persistent remission or 
requirements be before csDMARD can be tapered?
25. Are the Boolean remission criteria sufficiently well- defined?
26. Can taxonomy of RA be improved to guide therapeutic 
decisions?
box 1 Research agenda
1. Do we have enough data to recommend a specific treatment 
in patients with pre- rheumatoid arthritis (RA) at high risk to 
develop RA?
2. Is the application of a tumour necrosis factor (TNF) inhibitor 
after abatacept, tocilizumab, rituximab or a JAK inhibitor 
(JAKi) has failed, safe and efficacious?
3. How safe and efficacious are abatacept, tocilizumab and 
rituximab after any of the other non- TNF inhibitor- biological 
disease modifying antirheumatic drugs (b) DMARDs or a 
targeted synthetic (ts) DMARD has failed?
4. How safe and efficacious is the use of an interleukin 6 (IL-6) 
pathway inhibitor if another IL-6 pathway inhibitor/a JAKi 
has failed?
5. How safe and efficacious is the use of a JAKi after another 
JAKi has failed?
6. How safe and efficacious is the combination of a JAKi with a 
bDMARD, such as a TNF inhibitor?
7. Does the risk stratification for bDMARD/tsDMARD initiation 
based on presence of good or bad prognostic factors as 
recommended by European League Against Rheumatism 
translate into improved outcomes for both prognosis 
groups?
8. Do patients who lack poor prognostic factors benefit as 
much from a switch or addition of a conventional synthetic 
(cs) DMARD as from the addition of a bDMARD?
9. Is tapering of bDMARD monotherapy possible?
10. Will randomised controlled trials on tapering of bDMARDs or 
tsDMARDs designed to following predefined predictors for 
the maintenance of good outcomes after their withdrawal 
shows success?
11. How good is patient adherence to a bDMARD or tsDMARD 
and can non- adherence explain secondary loss of efficacy?
12. How can refractory RA be best defined, and what is the 
optimal treatment approach?
13. Can we identify new biomarkers to stratify patients and to 
predict therapeutic response and pending lack of response?
14. Which other factors, for example, lifestyle characteristics 
or treatment history or allow to make the best possible 
therapeutic decisions?
15. Do JAKi confer specific safety signals of concern?
16. What are the molecular pathways associated with 
thromboembolism when using JAKi?
17. Can the identification of disease phenotypes inform tailored 
therapeutic use?
18. Do the different bDMARDs/tsDMARDs lead to comparable 
improvements in comorbidities/multimorbidities?
19. Does the concomitant use of glucocorticoids at very low 
doses (1-3 mg prednisone equivalent) increase therapeutic 
success without producing unacceptable side effects?
20. Will therapeutic drug monitoring improve disease course 
and outcome and support decisions about switching within 
or between drugs?
21. Is leflunomide equivalent to methotrexate as first- line 
csDMARD therapy?
22. For active patients with RA who have failed multiple drugs, 
are there combinations that may be more successful such as 
JAKi with bDMARD?
23. Is secondary loss of efficacy due to non- adherence or a 
consequence of true loss of efficacy of a given drug and if 
the latter, what is the reason for this loss of efficacy?
Continued
strategies116; thus for cost and safety reasons, the committee still 
supports that bDMARD and tsDMARD rather than csDMARDs 
should be tapered first. Among the participants, 93% approved 
this change. LoE 1b, SoR A, LoA 9.2 (1.0).
12. If a patient is in persistent remission, tapering the csDMARD 
could be considered. While combining recommendations 11 and 
12 was discussed, the ultimate decision of the task force was to 
leave them separate and not change this item. This point relates 
primarily to two aspects: (1) in patients who have responded well 
to a csDMARD and did not need a bDMARD or tsDMARD, the 
csDMARD dose may be reduced in persistent remission and (2) 
in a patient who was on combination therapy and in whom slow 
dose reduction or interval increase of a bDMARD or tsDMARD 
has ultimately resulted in cessation of this added therapy with 
maintenance of persistent remission, one may consider also 
reducing the csDMARD dose. However, one needs to bear in 
mind that RA is regarded a usually incurable disease and that, 
therefore, a drug that has proven efficacy and is tolerated by 
the patient should not be stopped. With regards to the ques-
tion of stopping versus continuing csDMARDs in remission, no 
new trials have been found in the current SLR, an older trial 
comparing withdrawal versus continuation of csDMARDs in 
patients in remission found a significant increase in flare rate and 
restitution to the situation prior to discontinuation may not be 
as successful with csDMARDs as with bDMARD or tsDMARD 
reinstitution, since only half of the patients regained the previous 
state.117 118 Dose reduction, however, can be considered. LoE 2b, 
SoR B, LoA 9.0 (1.1).
Figure 1 depicts the algorithm based on the updated recom-
mendations. The figure is an abbreviated version of table 2 and 
the footnotes explain the definitions used. The research agenda 
(box 1) is an update of the previous version, of which several 
questions have been addressed over the last 3 years.
dIsCussIOn
Since the 2016 update, several new drugs have been approved in 
Europe. These new drugs are all within classes that had already 
been licensed for use in patients with RA, such as additional 
bsDMARDs inhibiting TNF; sarilumab, an anti- IL-6 receptor 
antibody that targets the same molecule as tocilizumab; and 
tofacitinib and baricitinib, two JAKis of which tofacitinib had 
already long been used in the USA and other regions of the 
world. Thus, major changes of these recommendations were 
not to be expected, but revisiting recommendations with respect 
to their timeliness is important to ensure that their evidence is 
maintained or strengthened or, when contradicting data become 
apparent, that they are amended to reflect the latest knowledge 
and evidence base.
The 2019 update of these recommendations, therefore, 
consolidates the previous efforts while adding one overarching 
principle (item D).
As before, the recommendations are ordered in terms of a 
sequential treatment strategy from the time point of diagnosis 
and the requirement to immediately start a DMARD therapy 
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(item 1) to the tapering of treatment once a stringent remission 
has been achieved (items 11, 12). Nine of the specific recom-
mendations were not changed (1–7, 9 and 12). The recom-
mendation to use MTX plus GC as an initial treatment strategy 
(5 and 6), while unchanged, has been reinforced by the task 
force; indeed, an abstract presented after the task force meeting 
revealed that MTX plus GC is non- inferior to three bDMARD 
MOAs combined with MTX, namely certolizumab (TNF), tocili-
zumab (IL- 6R) and abatacept (costimulation),71 confirming and 
further strengthening the task forces’ long- standing recommen-
dation in this respect. This recommendation relates to the initi-
ation of csDMARD therapy and bridging therapy with GC, not 
to long- term use of GC after the bridging period which may 
be afflicted with cardiovascular and other risks.34 119–121 In 
patients with early RA who fail MTX by 6 months, addition of 
bDMARDs/tsDMARDs is associated with a similar overall rate 
of LDA or remission at 12 months from treatment start as imme-
diately starting a TNFi plus MTX;72 it is conceivable that this 
also pertains to other agents, although such data are currently 
lacking. Thus, reduced response rates to subsequent therapies 
are primarily due to long disease duration and failure of several 
csDMARDs before initiation of a bDMARD or tsDMARD and 
not primarily a consequence of failing MTX.122
The task force maintained its recommendation to stratify 
patients who failed to attain the treatment target with the first 
treatment strategy into those with and those without poor prog-
nostic factors. The task force also reiterated its previous decision 
that bDMARDs and tsDMARDs should primarily be combined 
with csDMARDs, such as MTX, a decision now strengthened by 
the new SLR data allowing the LoE to rise from 1b to 1a also 
for tsDMARDs.
No evidence is available for switches between IL-6 receptor 
inhibitors or between JAKis. However, the task force assumed 
that these are similarly efficacious to switches for which direct 
evidence exists. This assumption was partly confirmed in a 
recent post hoc analysis of sarilumab in patients with an insuf-
ficient response to tocilizumab and trial showing efficacy of a 
bDMARD after an IR to a tsDMARD.104 105
Whereas the first 10 items address therapeutic strategies for 
patients with active RA from the time of diagnosis to failure of 
sequential therapies, the last two recommendations deal with 
patients in whom remission was attained. Tapering of bDMARDs 
and tsDMARDs should be cautious and only be started when 
stringent remission, such as based on the ACR- EULAR defini-
tions, is sustained. It should be noted that flares are frequent 
after withdrawal of bDMARDs and tsDMARDs and increase 
with time from cessation. There is no evidence supporting with-
drawal of csDMARDs before bDMARDs (or tsDMARDs), as 
also revealed by a recent trial comparing these two strategies.116 
Thus, maintaining a bDMARD or tsDMARD at a reduced dose 
or an expanded interval may be prudent.
Overall, the 2019 update reveals that various principles, such 
as the principle of (early) remission induction by virtue of T2T 
and the value of GCs and csDMARDs in this trajectory are 
firmly established. The ongoing development of new bDMARDs 
and tsDMARDs has allowed for an increasing proportion of 
patients to attain the treatment target. On the other hand, new 
bDMARDs and tsDMARDs primarily have access to the affluent 
markets because of their high price, thereby continuing to leave 
an unmet need in patients with RA in less affluent countries (most 
countries of the world) or in less affluent patients in high- income 
countries (such as in the USA). The task force considers this a 
challenge to organisations like EULAR, APLAR, PANLAR and 
ACR. Moreover, it appears that the financial benefits brought 
by the advent of more affordable bsDMARD to most European 
Union countries have not been seen in other regions to a nearly 
similar extent.
While recommendations presented in this update summarise 
the state of art from an evidence- driven point of view, they will 
always be aspirational in nature. They reflect ‘best practice’, 
provided in an ideal world in which physicians adhere to the 
principle of assessing the patients regularly and making decisions 
driven by these assessments. They assume that rheumatologists 
are aware of the various drugs’ safety issues, such as the risk 
of thromboembolic events on use of JAKi, especially in patients 
with cardiovascular risk factors, that was recently reported by 
regulators.53 88 93 They also assume patients adhere to the medi-
cation selected and prescribed in a shared decision process. In 
this imaginary world of ‘best practice’, costs are not a limiting 
factor. Such aspirational recommendations should be read as an 
encouragement to all that are involved in improving access to 
healthcare in less affluent situations.
Aspirational recommendations may have their downsides. 
They may inadvertently contribute to what is called by some ‘the 
race to the end’: the infinite search for ever subtler improve-
ments in efficacy and safety at ever higher expenses and attain-
able for ever fewer patients. Moreover, overdiagnosis and 
overtreatment123 may add to treatment inefficiency, risks and 
costs. It is the responsibility of the national and international 
professional societies to provide sufficient postgraduate educa-
tion and information on benefits and risks of available drugs, 
so that appropriate RA treatment is applied and thus not only 
stays manageable in terms of costs but also becomes attainable 
to those living in less affluent situations. This is conveyed with 
the present EULAR recommendations. Another good example of 
activities is the EULAR initiative to provide recommendations for 
difficult- to- treat RA,124 which will address the question if a once 
established diagnosis continues to be correct and will point to 
distinctions between inflammatory and non- inflammatory symp-
toms when deciding about T2T. In this respect, it is important to 
note that we are encountering an increasing number of patients 
who are ‘refractory’ to treatment or ‘difficult to treat’,124 125 and 
for whom the current recommendations also apply, provided a 
correct diagnosis and assessment of ongoing disease activity have 
been made. A correct diagnosis is key for the correct application 
of recommendations and appropriate use of medicines,20 which 
in RA means to combat inflammation. However, since refracto-
riness appears to be associated with treatment delays and high 
initial inflammatory load,125 rapid institution of appropriate 
treatment strategies once the diagnosis is made (recommenda-
tion 1) is of crucial importance.
In summary, the 2019 update of the EULAR recommenda-
tions provides rheumatologists, patients, health professionals 
and other stakeholders with the most recent evidence regarding 
the management of patients with RA. Adhering to these recom-
mendations, which are based on systematic literature reviews 
and opinions of experts from around the world, will allow 
optimal treatment of patients with RA at the beginning of the 
third decade of this century. Using the many therapeutic options 
available, the treatment target can be reached in most patients; 
however, about 20%–30% remain refractory to current thera-
pies.125 For these, new treatment options, but also better insights 
into the pathogenesis of RA will be needed. The research agenda 
points to unresolved questions and enables future task forces to 
further improve the EULAR recommendations.
As reflected by the current update in comparison with the 
previous one, for most of the therapeutic aspects of RA, we 
have reached a steady state of the evidence base for patients 
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with established RA, although still some needs remain unmet,126 
including the need to cure the disease. With the current rate of 
evidence development, we expect an update of the recommen-
dations to be necessary in about 3–4 years.
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